Background: Iron food fortification and oral iron formulations are frequently limited by poor absorption, resulting in the widespread use of high-dose oral iron, which is poorly tolerated. Methods: We evaluated novel iron-denatured whey protein (Iron-WP) microspheres on reactive oxygen species (ROS) and viability in gut epithelial (HT29) cells. We compared iron absorption from Iron-WP versus equimolar-dose (25 mg elemental iron) ferrous sulphate (FeSO4) in a prospective, randomised, cross-over study in fasting volunteers (n = 21 per group) dependent on relative iron depletion (a ferritin level ≤/>30 ng/mL). Results: Iron-WP caused less ROS generation and better HT29 cell viability than equimolar FeSO4. Iron-WP also showed better absorption with a maximal 149 ± 39% increase in serum iron compared to 65 ± 14% for FeSO4 (p = 0.01). The response to both treatments was dependent on relative iron depletion, and multi-variable analysis showed that better absorption with Iron-WP was independent of baseline serum iron, ferritin, transferrin saturation, and haemoglobin in the overall group and in the sub-cohort with relative iron depletion at baseline (p < 0.01). Conclusions: Novel Iron-WP microspheres may protect gut epithelial cells and improve the absorption of iron versus FeSO4. Further evaluation of this approach to food fortification and supplementation with iron is warranted.

1.
Guideline: Daily Iron Supplementation in Adult Women and Adolescent Girls. Geneva, World Health Organization, 2016.
2.
Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L: Iron deficiency anaemia. Lancet 2016;387:907-916.
3.
Sant-Ryan P, Drakesmith H, Black J, Hipgrave D, Biggs B: Control of iron deficiency anemia in low- and middle-income countries. Blood 2013;121:2607-2617.
4.
Jaeggi T, Kortman GA, Moretti D, Chassard C, Holding P, Dostal A, Boekhorst J, Timmerman HM, Swinkels DW, Tjalsma H, Njenga J, Mwangi A, Kvalsvig J, Lacroix C, Zimmermann MB: Iron fortification adversely affects the gut microbiome, increases pathogen abundance and induces intestinal inflammation in Kenyan infants. Gut 2015;64:731-742.
5.
Low MS, Speedy J, Styles CE, De-Regil LM, Pasricha SR: Daily iron supplementation for improving anaemia, iron status and health in menstruating women. Cochrane Database Syst Rev 2016;4:CD009747.
6.
Institute of Medicine Food and Nutrition Board: Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc: A Report of the Panel on Micronutrients. Washington, National Academy Press, 2001.
7.
Sinclair LM, Hinton PS: Prevalence of iron deficiency with and without anemia in recreationally active men and women. J Am Diet Assoc 2005;105:975-978.
8.
McNamee T, Hyland T, Harrington J, Cadogan S, Honari B, Perera K, Fitzgerald AP, Perry IJ, Cahill MR: Haematinic deficiency and macrocytosis in middle-aged and older adults. PLoS One 2013;8:e77743.
9.
Muñoz M, Villar I, García-Erce JA: An update on iron physiology. World J Gastroenterol 2009;15:4617-4626.
10.
Hentze MW, Muckenthaler MU, Galy B, Camaschella C: Two to tango: regulation of mammalian iron metabolism. Cell 2010;142:24-38.
11.
Chaplin S, Bhandari S: Oral iron: properties and current place in the treatment of anaemia. Prescriber 2012;23:12-18.
12.
Goddard AF, James MW, McIntyre AS, Scott BB: Gastroenterology. Guidelines for the management of iron deficiency anaemia. Gut 2011;60:1309-1316.
14.
Pereira D, Couto-Irving S, Lomer M, Powell J: A rapid, simple questionnaire to assess gastrointestinal symptoms after oral ferrous sulphate supplementation. BMC Gastroenterol 2014,14:103.
15.
Geisser P, Burckhardt S: The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics 2011;3:12-33.
16.
Walker S, Paton T, Cowan D, Manuel M, Dranitsaris G: Bioavailability of iron in oral ferrous sulfate preparations in healthy volunteers. CMAJ 1989;141:543-547.
17.
Zaim M, Piselli L, Fioravanti P, Kanony-Truc C: Efficacy and tolerability of a prolonged release ferrous sulphate formulation in iron deficiency anaemia: a non-inferiority controlled trial. Eur J Nutr 2012;51:221-229.
18.
Pereira D, Bruggraber S, Faria N, Poots L, Tagmount M, Aslam A, Frazer D, Vulpe C, Anderson G, Powell J: Nanoparticulate iron-III oxo-hydroxide delivers safe iron that is well absorbed and utilised in humans. Nanomedicine 2014;10:1877-1886.
19.
Martin A, de Jong G: Enhancing the in vitro iron(2+) bio-accessibility using ascorbate and cold-set whey protein gel particles. Dairy Sci Technol 2012;92:133-149.
20.
Remondetto GE, Beyssac E, Subirade M: Iron availability from whey protein hydrogels: an in vitro study. J Agric Food Chem 2004;52:8137-8143.
21.
Conway C, Geissler C, Hider R, Thompson R, Powell J: Serum iron curves can be used to estimate dietary iron bioavailability in humans. J Nutr 2006;136:1910-1914.
22.
Dale J, Burritt M, Zinsmeister A: Diurnal variation of serum iron, iron-binding capacity, transferrin saturation, and ferritin levels. Am J Clin Pathol 2002;117:802-808.
23.
Friedman A, Shander A, Martin S, Calabrese R, Ashton M, Lew I, Seid M, Goodnough L: Iron deficiency anemia in women: a practical guide to detection, diagnosis, and treatment. Obstet Gynecol Surv 2015;70:342-353.
24.
Skikne BS, Punnonen K, Caldron PH, Bennett MT, Rehu M, Gasior GH, Chamberlin JS, Sullivan LA, Bray KR, Southwick PC: Improved differential diagnosis of anemia of chronic disease and iron deficiency anemia: a prospective multicenter evaluation of soluble transferrin receptor and the sTfR/log ferritin index. Am J Hematol 2011;86:923-927.
25.
Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P: Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436-2448.
26.
Galan P, Yoon HC, Preziosi P, Viteri F, Valeix P, Fieux B, Briançon S, Malvy D, Roussel AM, Favier A, Hercberg S: Determining factors in the iron status of adult women in the SU.VI.MAX study. Eur J Clin Nutr 1998;52:383-388.
27.
Schultink W, van der Ree M, Matulessi P, Gross R: Low compliance with an iron-supplementation program: a study among pregnant women in Jakarta, Indonesia. Am J Clin Nutr 1993;57:135-139.
28.
Donovan A, Lima CA, Pinkus JL, et al: The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab 2005;1:191-200.
29.
Xu R, Liu N, Xu X, Kong B: Antioxidative effects of whey protein on peroxide-induced cytotoxicity. J Dairy Sci 2011;94:3739-3746.
30.
Haider BA, Olofin I, Wang M, Spiegelman D, Ezzati M, Fawzi WW: Anaemia, prenatal iron use, and risk of adverse pregnancy outcomes: systematic review and meta-analysis. BMJ 2013;346:f3443.
31.
Toxqui L, Pérez-Granados AM, Blanco-Rojo R, Wright I, Vaquero MP: A simple and feasible questionnaire to estimate menstrual blood loss: relationship with hematological and gynecological parameters in young women. BMC Womens Health 2014;14:71.
32.
Kuang S, Oliveira J, Crean A: Microencapsulation as a tool for incorporating bioactive ingredients into food. Crit Rev Food Sci Nutr 2010;50:951-968.
33.
Bloom KA, Huang FR, Bencharitiwong R, Bardina L, Ross A, Sampson HA, Nowak-Węgrzyn A: Effect of heat treatment on milk and egg proteins allergenicity. Pediatr Allergy Immunol 2014;25:740-746.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.